Physician profile
Danielle D Angeron
NPI 1508059536
$1,258.80
in general payments reported to CMS, 2019-2025
17 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2021: $43.61 · 2022: $115 · 2023: $342 · 2024: $270 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844 · Education: $90.00 · Travel and Lodging: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.02 |
| Education | $90.00 |
| Travel and Lodging | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.97 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $260.39 | 2019-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $159.74 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $108.72 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.07 | 2019 | |
| Glaxosmithkline, LLC. | $16.44 | 2019 | |
| Radius Health, INC. | $16.29 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.89 | 2022 | |
| Organon LLC | $15.73 | 2021 | |
| Pfizer INC. | $15.23 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $14.79 | 2023 | Farxiga |
| Circassia INC. | $13.67 | 2019 | |
| Amgen INC. | $12.08 | 2019 | |
| Allergan, INC. | $11.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.93 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $11.09 | 2021 | |
| Amarin Pharma, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Angeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.